VSIR and cancer: Liu and colleagues reported a nonredundant, T cell-activating role for VISTA that is distinct from the PD-1/PD-L1 pathway [8]; this provided a rationale for the combined targeting of the VISTA and PD-1 pathways when treating patients with cancer.